Physician profile
Alexander Martinez
NPI 1477115285
$3,443.27
in general payments reported to CMS, 2019-2025
17 companies · $690 in 2025
The $690 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.72 · 2020: $173 · 2021: $75.20 · 2022: $602 · 2023: $1,236 · 2024: $636 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,119.67 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $699.58 | 2022-2025 | Total30, Dailies Total1, Precision 1 |
| Abbvie INC. | $369.75 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $246.35 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150.72 | 2020 | |
| Dompe US, INC. | $149.50 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $131.98 | 2023-2025 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $127.09 | 2024 | Syfovre |
| Astellas Pharma US INC | $121.85 | 2023 | Izervay |
| Allergan, INC. | $97.31 | 2022 | |
| Sun Pharmaceutical Industries INC. | $92.73 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $41.71 | 2020-2022 | |
| Horizon Therapeutics Plc | $30.88 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $21.40 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.86 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $15.56 | 2022 | |
| Visioneering Technologies, INC. | $8.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.